Pioglitazone is a PPAR (peroxisome proliferator-activated receptor)-gamma agonist of the thiazolidinedione class that is used to treat insulin resistance in patients with Type 2 diabetes. Prior studies in the MPTP mouse model reported that the drug prevented dopaminergic cell loss in the substantia nigra (Breidert et al. J Neurochem 2002;82:615-624). The implication was that the drug might be usefully employed as a neuroprotective agent in Parkinson’s disease. Read More
Latest News
AAN 2016 DAILY REPORT
April 21, 2016
Monday Edition
Tuesday Edition
Wednesday Edition
American Academy of Neurology, Vancouver, B.C., 15-21 April 2016
CONGRESS HIGHLIGHTS – WEDNESDAY EDITION Read More
Growing evidence of traumatic brain injury as a PD risk factor
April 13, 2016Traumatic brain injury has been an important focus at the American Academy of Neurology annual meeting, and new data are expected at AAN 2016 later this month in Vancouver. Read More
Off-target effects proposed as reason for phase I study death
April 6, 2016Off-target drug effects may be the reason for the phase I accident in France that left one person dead and five others hospitalized (see 1 dead in phase I trial, NeuroSens, January 27, 2016). However, other causes are also being explored by the 12-person Temporary Specialist Scientific Committee (TSSC) set up by France’s Agence national de securité du medicament et des produits du santé (ANSM). Read More